MediWound Ltd. (MDWD)
After hours:
| Previous Close | 19.37 |
| Open | 19.54 |
| Bid | 19.62 x 200 |
| Ask | 19.87 x 200 |
| Day's Range | 19.11 - 19.86 |
| 52 Week Range | 7.10 - 24.00 |
| Volume | |
| Avg. Volume | 165,693 |
| Market Cap | 183.815M |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.36 |
| Earnings Date | Aug 13, 2024 - Aug 19, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.75 |
GlobeNewswireMediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
Funds to be used for clinical development of EscharEx® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, announced today it has been selected to receive €16.25 million in blended funding from the European Innovation Council (EIC) through its accelerator
PR NewswireMölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd
Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an investment of US $15m in MediWound Ltd. (Nasdaq: MDWD) (MediWound) through a definitive share purchase agreement in a private investment in public equity (PIPE). MediWound, a global leader in next-generation enzymatic therapeutics focused on non-surgical wound debridement, has a vision to improve the existing standards of care and patient experiences, while
- GlobeNewswire
MediWound Announces $25 Million Strategic Private Placement Financing
Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investmentYAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a definitive share purchase agreement with several new and existing investors, including Mölnlycke Health Care ("Mölnlycke"), a world-leading MedTech company specializing in solutions for
